Form 8-K - Current report:
SEC Accession No. 0001628280-21-024264
Filing Date
2021-12-01
Accepted
2021-11-30 17:52:59
Documents
15
Period of Report
2021-11-30
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K cpix-20211130.htm   iXBRL 8-K 37331
2 EX-99.1 a11-29x21ex991.htm EX-99.1 19988
7 image_1.jpg GRAPHIC 23268
  Complete submission text file 0001628280-21-024264.txt   252459

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20211130.xsd EX-101.SCH 2265
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cpix-20211130_def.xml EX-101.DEF 13058
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20211130_lab.xml EX-101.LAB 26049
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20211130_pre.xml EX-101.PRE 13936
8 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20211130_htm.xml XML 11013
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 211460631
SIC: 2834 Pharmaceutical Preparations